ProMIS Neurosciences Company Leadership
| PMN Stock | USD 15.25 0.29 1.94% |
ProMIS Neurosciences' insiders are aggressively buying. The analysis of the overall insider sentiment regarding ProMIS Neurosciences suggests that virtually all insiders are extremely bullish. ProMIS Neurosciences employs about 7 people. The company is managed by 12 executives with a total tenure of roughly 17 years, averaging almost 1.0 years of service per executive, having 0.58 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2026-02-03 | Abg Management Ltd. | Acquired 700741 @ 12.13 | View | ||
| 2025-10-03 | Max A Milbury | Acquired 1215 @ 12.25 | View |
Monitoring ProMIS Neurosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. ProMIS Neurosciences Management Team Effectiveness
The company has Return on Asset of (0.8538) % which means that on every $100 spent on assets, it lost $0.8538. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (3.558) %, meaning that it generated no profit with money invested by stockholders. ProMIS Neurosciences' management efficiency ratios could be used to measure how well ProMIS Neurosciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, ProMIS Neurosciences' Return On Tangible Assets are very stable compared to the past year. As of the 16th of February 2026, Return On Assets is likely to grow to 0.14, while Return On Capital Employed is likely to drop (0.95). At this time, ProMIS Neurosciences' Return On Assets are very stable compared to the past year.As of the 16th of February 2026, Common Stock Shares Outstanding is likely to grow to about 1.3 M, while Net Loss is likely to drop (17.1 M). The market capitalization of ProMIS Neurosciences is $32.82 Million. Over half of ProMIS Neurosciences' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Note, that even with substantial debt, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company at some point.
Shares in Circulation | First Issued 2005-06-30 | Previous Quarter 1.4 M | Current Value 1.4 M | Avarage Shares Outstanding 427.6 K | Quarterly Volatility 2.1 M |
ProMIS Neurosciences Workforce Comparison
ProMIS Neurosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 838. ProMIS Neurosciences maintains roughly 7.0 in number of employees contributing less than 1% to equities under Health Care industry.
ProMIS Neurosciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProMIS Neurosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProMIS Neurosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ProMIS Neurosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-09-01 | 1.75 | 21 | 12 | 13,417,110 | 4,904,844 |
| 2025-06-01 | 5.0 | 5 | 1 | 100,000 | 93,223 |
| 2025-03-01 | 1.0 | 1 | 1 | 15,000 | 48,333 |
| 2024-09-01 | 7.3333 | 22 | 3 | 8,114,847 | 1,150,000 |
| 2023-12-01 | 1.75 | 7 | 4 | 215,000 | 1,447,872 |
| 2023-09-01 | 10.0 | 10 | 1 | 181,584 | 0.00 |
| 2022-09-01 | 0.1 | 3 | 30 | 213,334 | 534,951 |
ProMIS Neurosciences Notable Stakeholders
A ProMIS Neurosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ProMIS Neurosciences often face trade-offs trying to please all of them. ProMIS Neurosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ProMIS Neurosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Neil MD | CoChairman CoFounder | Profile | |
| Eugene Williams | CoFounder Chairman | Profile | |
| Neil MBA | Interim President | Profile | |
| Gail Farfel | Chief Officer | Profile | |
| Daniel MBA | Chief Officer | Profile | |
| Johanne Kaplan | Chief Officer | Profile | |
| Dennis Chen | Head Consultant | Profile | |
| David Wishart | Chief Officer | Profile | |
| MBA MBA | Chief Officer | Profile | |
| Gavin Malenfant | Chief Officer | Profile | |
| Ernest Bush | Head Consultant | Profile | |
| Larry MD | Chief Officer | Profile |
About ProMIS Neurosciences Management Performance
The success or failure of an entity such as ProMIS Neurosciences often depends on how effective the management is. ProMIS Neurosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ProMIS management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ProMIS management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.13 | 0.14 | |
| Return On Capital Employed | (0.91) | (0.95) | |
| Return On Assets | 0.13 | 0.14 | |
| Return On Equity | 0.15 | 0.16 |
ProMIS Neurosciences Workforce Analysis
Traditionally, organizations such as ProMIS Neurosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ProMIS Neurosciences within its industry.ProMIS Neurosciences Manpower Efficiency
Return on ProMIS Neurosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Income Per Employee | 397K | |
| Net Income Per Executive | 231.6K | |
| Working Capital Per Employee | 2.4M | |
| Working Capital Per Executive | 1.4M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Will Biotechnology sector continue expanding? Could ProMIS diversify its offerings? Factors like these will boost the valuation of ProMIS Neurosciences. Anticipated expansion of ProMIS directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ProMIS Neurosciences data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
ProMIS Neurosciences's market price often diverges from its book value, the accounting figure shown on ProMIS's balance sheet. Smart investors calculate ProMIS Neurosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since ProMIS Neurosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between ProMIS Neurosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ProMIS Neurosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.